Rznomics Overview

  • Year Founded
  • 2017

Year Founded

  • Status
  • Private

  • Employees
  • 34

Employees

  • Latest Deal Type
  • Grant

  • Latest Deal Amount
  • $8M

  • Investors
  • 18

Rznomics General Information

Description

Developer of ribonucleic acid-based gene therapies designed to create new bio drugs for cancer and intractable diseases with highly medical unmet needs. The company develops therapeutic products for the treatment of various cancers, degenerative neurological diseases, and hereditary diseases, enabling medical practitioners to treat cancerous and Alzheimer's diseases.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 152 Jukjeon-ro, Suji-gu
  • Gyeonggi-do, Dankook University Software ICT Building 327
  • Yongin, Suji-gu 16890
  • South Korea
+82
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Other Healthcare Technology Systems
Vertical(s)
LOHAS & Wellness, HealthTech, Life Sciences, Oncology
Corporate Office
  • 152 Jukjeon-ro, Suji-gu
  • Gyeonggi-do, Dankook University Software ICT Building 327
  • Yongin, Suji-gu 16890
  • South Korea
+82

Rznomics Timeline

2021202220232024
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Rznomics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Grant 27-Sep-2023 $8M Completed Clinical Trials - Phase 1
6. Later Stage VC (Series C) 07-Jun-2022 Completed Clinical Trials - Phase 1
5. Early Stage VC (Series B) 05-Apr-2021 Completed Clinical Trials - Phase 1
4. Early Stage VC (Series A) 19-Sep-2019 Completed Clinical Trials - Phase 1
3. Early Stage VC 17-Jul-2018 Completed Clinical Trials - Phase 1
2. Accelerator/Incubator 22-Dec-2017 $183K Completed Startup
1. Seed Round 20-Dec-2017 $183K $183K Completed Startup
To view Rznomics’s complete valuation and funding history, request access »

Rznomics Patents

Rznomics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4382135-A1 Cancer-specific trans-splicing ribozyme as gene therapy product combined with radiotherapy Pending 06-Aug-2021
US-20230212574-A1 Construct of self-circularization rna Active 10-Mar-2021
AU-2022234607-A1 Self-circularized rna structure Pending 10-Mar-2021
CA-3178127-A1 Self-circularized rna structure Pending 10-Mar-2021
EP-4116421-A1 Self-circularized rna structure Pending 10-Mar-2021 C12N15/67
To view Rznomics’s complete patent history, request access »

Rznomics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Rznomics Investors (18)

Investor Name Investor Type Holding Investor Since Participating Rounds
Korean government Government
AON Investment Venture Capital Minority
IBK Capital (Korea) Lender/Debt Provider Minority
QUAD Ventures Venture Capital Minority
Samsung Securities Corporation Minority
You’re viewing 5 of 18 investors. Get the full list »

Rznomics FAQs

  • When was Rznomics founded?

    Rznomics was founded in 2017.

  • Where is Rznomics headquartered?

    Rznomics is headquartered in Yongin, South Korea.

  • What is the size of Rznomics?

    Rznomics has 34 total employees.

  • What industry is Rznomics in?

    Rznomics’s primary industry is Drug Discovery.

  • Is Rznomics a private or public company?

    Rznomics is a Private company.

  • What is Rznomics’s current revenue?

    The current revenue for Rznomics is .

  • How much funding has Rznomics raised over time?

    Rznomics has raised $49.8M.

  • Who are Rznomics’s investors?

    Korean government, AON Investment, IBK Capital (Korea), QUAD Ventures, and Samsung Securities are 5 of 18 investors who have invested in Rznomics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »